Prevalence of smoking, passive smoke exposure, and vaping among adults with cystic fibrosis
Study of the Prevalence of Active/Passive Smoking and Vaping Among Patients With Cystic Fibrosis
This project will see how common smoking, exposure to secondhand smoke, and vaping are among adults with cystic fibrosis followed at the Strasbourg Adult CF Center.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Strasbourg, France Academic / other |
| Locations | 1 site (Strasbourg) |
| Trial ID | NCT07342920 on ClinicalTrials.gov |
What this trial studies
This is an observational, cross-sectional collection of data on active smoking, passive smoke exposure, and e-cigarette use in adults with confirmed cystic fibrosis who receive regular care at the Strasbourg Adult Cystic Fibrosis Center. Participants will be adults (≥18) with confirmed CF; patients with prior double lung transplantation are excluded. Information will be gathered by questionnaires and chart review to quantify prevalence and patterns of tobacco and vaping exposure. The findings aim to fill a gap in French data and to inform local tobacco-prevention and clinical counseling, including considerations about interactions with CFTR modulators such as Kaftrio.
Who should consider this trial
Good fit: Adults (age ≥18) with confirmed cystic fibrosis who attend regular follow-up at the Strasbourg Adult Cystic Fibrosis Center are the intended participants.
Not a fit: People under 18, patients not followed at the Strasbourg center, and those who have had a double lung transplant are unlikely to benefit directly from this study's findings.
Why it matters
Potential benefit: If successful, the study could identify how common smoking and vaping are in this population and guide targeted tobacco-prevention and counseling efforts to improve respiratory health and treatment effectiveness.
How similar studies have performed: International studies have reported links between smoking/vaping and outcomes or CFTR modulator effectiveness, but comprehensive prevalence data in French adult CF cohorts are limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patient (≥ 18 years old) * With confirmed cystic fibrosis * Regular follow-up at the Strasbourg Adult Cystic Fibrosis Center Exclusion Criteria: * Patients who have undergone a double lung transplant for cystic fibrosis.
Where this trial is running
Strasbourg
- Service de Pneumologie - CHU de Strasbourg - France — Strasbourg, France (Recruiting)
Study contacts
- Study coordinator: Romain Kessler, MD, PhD
- Email: Romain.Kessler@chru-strasbourg.fr
- Phone: 33 3 69 55 03 77
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.